Drugs / GT801
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07614191 | May 2026 → Dec 2031 expected | — | Vivacta Biotechnology (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT07333118 | Nov 2025 → Mar 2028 expected | — | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 0 | NCT07205315 | Sep 2025 → Nov 2027 expected | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, autoimmune hemolytic anemia | Grit Biotechnology | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Grit Biotechnology | Results NHL患者ORR100%、CR率75%，微滔In-vivo CAR-T人体数据亮相ASCO gritbio.com ↗
初步疗效数据显示，4例患者客观缓解率（ORR）达到100%，其中3例患者最终达到完全缓解（CR）。 |
| 2026-04-22 | Grit Biotechnology | Results 从Kelonia到Orna：当巨头同时押注两条路径——礼来收购Kelonia背后的真正信号 gritbio.com ↗
优化后的mRNA设计使T-LNP平台可在人PBMC中实现超过14天的CAR表达。 |
| 2025-10-31 | Grit Biotechnology | Results 沙砾生物多项科学突破入选SITC 2025大会报告 gritbio.com ↗
在hHSC重建小鼠中，GT801在0.01 mg/kg极低剂量水平单次给药，可快速清除>95% 的B细胞，并促进T细胞扩增约30倍，证明了T细胞在体内转染后的良好状态和扩增能力。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Grit Biotechnology | NHL患者ORR100%、CR率75%，微滔In-vivo CAR-T人体数据亮相ASCO gritbio.com ↗ |
| 2026-04-22 | Grit Biotechnology | 从Kelonia到Orna：当巨头同时押注两条路径——礼来收购Kelonia背后的真正信号 gritbio.com ↗ |
| 2025-10-31 | Grit Biotechnology | 沙砾生物多项科学突破入选SITC 2025大会报告 gritbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07614191 ↗ |